Skip to main content

Table 1 Clinical characteristics of the study population

From: Longitudinal analysis of healthy colon establishes aspirin as a suppressor of cancer-related epigenetic aging

Characteristic No. subjects
Time point 1 (t1)a Time point 2 (t2)b
Aspirin regular usec
Nonuserd 14 (45%) 11 (35%)
Long-term user (≥ 2 year)e 17 (55%) 20 (65%)
Age 50–70 (median 55) 60–80 (median 65)
BMIf   
 Normal (18.5–25) 16 (52%) 14 (45%)
 High (≥ 26) 15 (48%) 17 (55%)
Polyps
 No polyps 18 (58%) 23 (74%)
 Yes 13 (42%) 8 (26%)
Proximalg
 Tubular adenoma 3 (23%) 1 (12.5%)
 Serrated lesionh 1 (8%) 0 (0%)
 Hyperplastic 1 (8%) 0 (0%)
 Serrated adenoma 0 (0%) 0 (0%)
 Mixed 0 (0%) 1 (12.5%) TA and SA
distali
 Tubular adenoma 4 (31%) 4 (50%)
 Serrated lesion 5 (38%) 0 (0%)
 Hyperplastic 4 (31%) 0 (0%)
 Serrated adenoma 1 (7%) 0 (0%)
 Mixed 0 (0%) 1 (12.5%) TA and HP
 Proximal and distal 0 (0%) 1 (12.5%) TA
  1. aBaseline time point
  2. b10-year follow-up
  3. cRegular use defined as ≥ 2 tablets/week for ≥ 1 month
  4. dNonuser: women who indicated that they did not use the aspirin ≥ 2 tablets/week for ≥ 1 month (“minimum level”)
  5. eLong-term user: women who indicated that they used the aspirin ≥ 2 tablets/week for ≥ 2 years
  6. fBMI: body mass index; height (cm) and weight (kg) were self-reported and BMI was calculated (kg/m2) from these variables
  7. gProximal: cecum
  8. hSerrated lesion: any serrated polyp including hyperplastic and serrated adenoma
  9. iDistal: sigmoid colon